Dr. Lihi Eder discusses the differences between sex and gender. Sex is a biologically-based construct defining differences between male and female Gender has socio-cultural aspects of being a man, woman, or other AND has effect on social norms/expectations BOTH are important to… https://t.co/iceTS0w5LY https://t.co/slSQMwF91J

Differences in PsA: Women tend to have higher pain scores with lower pain thresholds and are more likely to report "diffuse pain" compared to men. Keep this in mind with your assessments. Remember mimics of sacroiliitis including osteitis condensas ilii. Look at the imaging below… https://t.co/AUjkQwfSuk https://t.co/5iXx5cxm4U

BASDAI tends to be higher in women while there is no appreciable difference in ASDAS scoring in men compared to women. Dr. L. Eder believes this could be due to the pain scoring in both indices. #RNL2024 @RheumNow @lihi_eder https://t.co/i7XPenrmGG

Did you know the majority of lecturers at #RNL2024 are women? #StrongWomenLeaders @ACRheum #RNL2024 #WomenChangingLives @rheumnow https://t.co/0TO8XUhhg5

With regard to SpA patient journey: On average, women are diagnosed 2.3 years later than men. Additionally, women tend to have more visits to rheumatology to reach diagnosis of PsA, AS, and RA! Remember your inherent bias along with sex/gender disparities. Dr. L. Eder… https://t.co/o0Hv3NrXpB https://t.co/vsMN3HkSv6

Did you know? There is very limited reporting of sex-disaggregated RCT results, data necessary from an FDA standpoint. Dr. L. Eder points out the importance of this data from a clinical standpoint. Let's do better! #RNL2024 @RheumNow @lihi_eder https://t.co/3FETZZWt0B

This is the risk. We have to be aware and better at this in order to serve our female patients better @lihi_eder @RheumNow #RNL2024 https://t.co/7JIDtlSGXh

The panel addresses the question about using combination biologics and combo tsDMARDS + biologic. These combos are being studied. The panel noted combo apremilast +biologic is pretty commonly used appears to be effective and safe. #RNL2024 @rheumnow https://t.co/EeIlhJiDZU

Dr. Eder noted in her metanalysis of treatment efficacy in PsA based on gender – women had poorer response to treatments; the placebo effects are the same between men and women, suggesting a biologic mechanism and rather than a “psychosomatic” effect. #RNL2024 @rheumnow https://t.co/3H2Nfamg70

My volume of referrals for OCI or degenerative disease (or sometimes completely normal SI joints) read as "sacroiliiitis" really does seem to have been increasing lately @lihi_eder @RheumNow #RNL2024 https://t.co/vksNCaADck

👉“Eighty percent of drugs withdrawn from the market pose greater risk for women.” – Dr. Eder #RNL2024 @rheumnow #genderDifferences https://t.co/RZrIdvecbY

Welcome to the "FDA-approved" team Bimekizumab. Dr. Armstrong shows MOA of IL17a and IL17f dual inhibition, and the important PASI scores showing 2/3 of pts clear by week 16. @RheumNow #RNL2024 @_AprilArmstrong https://t.co/KiTcVsGzpD